Spasmalgon, tablets 20 pcs

Spasmalgon is a spasmoanalgesic of combined composition.

Methamisole sodium is a derivative of pyrazolone. It has analgesic, antipyretic and anti-inflammatory effects, the mechanism of which is associated with inhibition of prostaglandin synthesis.

Pitophenone hydrochloride is a myotropic antispasmodic; it has a direct effect on the smooth muscles of internal organs and causes their relaxation.

Phenpiperinia bromide, being a m-cholinoblocker, has an additional relaxing effect on the smooth muscles.

The combination of the three components of the drug leads to a mutual enhancement of their pharmacological action.

Indications

Active ingredient

Composition

Active ingredients:

Sodium metamizole 500 mg;

Pitophenone hydrochloride 5 mg;

Phenpiperinia bromide 0.1 mg.

Auxiliary substances:

Lactose monohydrate 10 mg,

Wheat starch 85.9 mg,

Talc (magnesium disilicate) b mg,

magnesium stearate 4 mg,

gelatin 4 mg,

sodium hydrogen carbonate 5 mg.

How to take, the dosage

Orally.

Adults and children over 15 years

1-2 tablets 2-3 times a day. The drug is best taken after a meal with water. Daily dose should not exceed 6 tablets. The duration of treatment should not exceed 5 days. Increasing the daily dose of the drug or the duration of treatment is possible only under the supervision of a doctor.

In children under 15 years of age

In children, the drug is used only with a doctor’s prescription.

Other dosage regimens are possible only after consultation with your doctor.

Interaction

Simultaneous use of Spasmalgon with other non-narcotic analgesics may lead to mutual enhancement of toxic effects.

Sedatives and tranquilizers increase the analgesic effect of sodium metamizole.

Tricyclic antidepressants, oral contraceptives, allopurinol impair metabolism of metamizole in the liver and increase its toxicity.

Barbiturates, phenylbutazone and other inducers of microsomal liver enzymes weaken the effects of sodium metamizole.

Rentgen contrast drugs, colloidal blood substitutes and penicillin should not be used during treatment with drugs containing sodium metamizole.

Simultaneous use with cyclosporine reduces the blood level of the latter.

Sodium metamizole displaces oral hypoglycemic drugs, indirect anticoagulants, glucocorticoids and indomethacin from binding to plasma proteins and may increase their potency.

When co-administered with N 1 -histamine receptor blockers, butyrophenones, phenothiazines, tricyclic antidepressants, amantadine and quinidine may increase m-cholinoblocking action.

It enhances the effects of ethanol.

Concomitant use with chlorpromazine or other phenothiazine derivatives may result in marked hyperthermia.

Thiamazole and cytostatics increase the risk of leukopenia. The effect is increased by codeine, H 2 -histamine receptor blockers and propranololol (delays inactivation of sodium metamizole).

The physician should be consulted if simultaneous use of the above and other medicinal products is necessary.

Special Instructions

In patients suffering from bronchial asthma, taking the drug may provoke a seizure.

When using the drug it is necessary to monitor the peripheral blood picture (leukocyte count) and the functional state of the liver.

In case of suspected agranulocytosis or thrombocytopenia the drug should be discontinued.

Alcohol should not be taken during treatment with the drug.

The effect of the drug on the ability to drive vehicles and other mechanisms requiring high concentration

When taking the drug, it is not recommended to drive vehicles and engage in potentially dangerous activities requiring rapid physical and mental reaction.

Contraindications

Side effects

Nervous system disorders: headache, dizziness, anticholinergic effects (decreased sweating, accommodation paresis, difficulty in urination).

Cardiovascular system: decreased blood pressure, tachycardia, cyanosis.

Urinary system disorders: impaired renal function, oliguria, anuria, proteinuria, interstitial nephritis, staining of urine red.

Hematopoietic organs: with prolonged use – thrombocytopenia, leukopenia, agranulocytosis.

Allergic reactions: urticaria, bronchospastic syndrome, anaphylactic shock, Quincke’s edema, erythema multiforme (including Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell’s syndrome).

Overdose

Symptoms: vomiting, dry mouth, decreased perspiration, impaired accommodation, decreased blood pressure, drowsiness, confusion, liver and kidney dysfunction, seizures.

Treatment: gastric lavage, administration of activated charcoal, symptomatic therapy.

Pregnancy use

It is contraindicated in pregnancy.

Breastfeeding should be stopped during treatment.

Similarities